HIMS Commentator
TSLL Gain HunterJust looked up that Hims' CPO (Chief Policy Officer) Deb Autor worked at the FDA for seven years. Deputy Commissioner for Global Regulatory Operations and Policy | 2011 – 2013. One of the FDA's senior leaders, responsible for overseeing global inspections, criminal investigations, and international operations.
Director, Office of Compliance, Center for Drug Evaluation and Research (CDER) | 2006 – 2011. Responsible for drug approval, GMP (Good Manufacturing Practice), clinical trial monitoring, and enforcement against internet/health fraud.
It was already named and warned by the FDA last year (and just got criticized again). Before deciding to launch the generic drug this time, didn't even one person from the legal team and the marketing team raise any objections? $Hims & Hers Health(HIMS.US)$Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)
+1
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
